Exyn is leveraging its autonomous navigation and mapping technology to expand from mining into geospatial, construction, and defense markets, with geospatial expected to drive the most rapid growth. The company is transitioning to a recurring software revenue model, supported by strong partnerships…
Q2 2026 results exceeded expectations with 7% revenue growth, strong margins, and robust cash flow. AI-driven demand boosted data platform performance, and guidance for the full year was raised. Leverage improved, and disciplined capital allocation continues.Based on Progress Software Corporation…
Alcoa will acquire South32's bauxite, alumina, and aluminum assets for $4.1 billion in cash and stock, plus a contingent value right of up to $750 million, aiming for $900 million in synergies and immediate accretion to earnings. The deal strengthens global scale and is set to close in H1 2027.Orig…
A $4.1B acquisition of bauxite, alumina, and aluminum assets will expand production capacity, generate $900M in synergies, and strengthen cost competitiveness. The deal is expected to close in H1 2027, enhancing market position and long-term growth prospects.Original document: Alcoa Corporation [AA…
The conference highlighted strong execution on pivotal cema-cel trials, rapid MRD testing adoption, and a sizable market opportunity. Interim data showed high MRD clearance and excellent safety, while ALLO-329's dual-targeting and Dagger technology drive innovation in autoimmune indications.Based o…
Revenue grew 3.7% year-over-year to JPY21.9 billion, with net income attributable to ordinary shareholders up 20.4%. Gross margin improved to 36.8%, and the company completed a successful IPO in May 2026, raising $26.2 million.Original document: Micware Co., Ltd. [MWC] SEC 6-K Current Report — Jul…
Net revenue declined sharply year-over-year due to lower supplement sales and no diagnostic services revenue. The company reported a $5.4 million net loss from continuing operations and faces significant liquidity and going concern risks, while focusing on genomics and new diagnostics commercializa…
The conference highlighted a strong focus on executing the pivotal cema-cel trial in lymphoma, with interim data showing high MRD clearance and excellent safety. Rapid MRD adoption and community access drive a multi-billion dollar market opportunity, while the autoimmune pipeline advances with inno…
Gross margin improved to 35% in May, with revenue run rate rising to $35–36 million due to new distributor partnerships and strong B2B/B2C growth. NEXUS launch is driving sales, while SOLIS and COR marketing will intensify in H2. Management targets operational cash flow positivity within 12 months…
Revenue fell 41% year-over-year to $2.95 million, with a net loss of $18.8 million amid restructuring and major acquisitions. Liquidity remains a concern, with substantial doubt about the company’s ability to continue as a going concern, and SG Echo’s Chapter 11 filing further impacts operations.Or…
Full year revenue was flat at $46.4B, with net income down 3% to $3.1B. Q4 results were boosted by a $986M IEEPA tariff recovery, driving net income up 407%. Management remains focused on profitability and long-term growth amid challenging market conditions.Original document: Nike, Inc. [NKE] SEC 8…
Reported EPS grew 31% to $3.79, with net sales of $2.43B (down 3% but organic up 3%). Beer segment led growth, while Wine & Spirits saw organic gains despite divestitures. Fiscal 2027 EPS outlook raised, with strong cash flow and continued shareholder returns.Original document: Constellation Brands…
Q2 2026 revenue rose 7% year-over-year to $253.5M, driven by strong software license sales and favorable currency impact. Net income increased to $21.1M, with ARR up 2% to $868M and robust cash flow. Ongoing MOVEit litigation and restructuring actions remain key risks.Original document: Progress So…
Q2 2026 saw 7% revenue growth to $253M, ARR up 2% to $868M, and non-GAAP EPS of $1.62, all above guidance. Operating margin reached 40%, with strong cash flow and continued focus on M&A, debt repayment, and share repurchases. Guidance for FY 2026 was raised.Original document: Progress Software Corp…
Micware secured a JPY 3 billion revolving credit facility with MUFG Bank, Ltd., backed by joint and several guarantees from group companies, to support working capital needs. The agreement includes strict financial and non-financial covenants, staged lending limits, and robust reporting and complia…
Q2 2026 saw 7% revenue growth and strong AI-driven demand, with EPS and cash flow up sharply year-over-year. Guidance for FY 2026 was raised, reflecting confidence in continued growth and operational discipline. Net leverage fell to 2.9x and share repurchases continued.Original document: Progress S…
Two pivotal cell therapy programs are advancing, with LYL273 showing strong response rates and safety improvements in metastatic colorectal cancer and ronde-cel leading in large B-cell lymphoma. Key data updates and a BLA submission are expected within the next year, positioning both products for c…
Drilling at Dumbwa has now defined 6.7 km of mineralized strike, with systematic expansion northward and early 3D modeling confirming a large, stratified copper system. High-grade zones are comparable to Lumwana, with ongoing metallurgical testing and a maiden MRE planned after Phase I drilling.Bas…
Two pivotal cell therapy programs are advancing, with LYL273 showing strong response rates and safety improvements in metastatic colorectal cancer and ronde-cel leading in large B-cell lymphoma. Major data updates and a BLA submission are expected within the next year, positioning the company for c…
A novel CD19-directed CAR-NK cell therapy is advancing through multiple autoimmune disease trials, with a focus on safety, outpatient accessibility, and durable remissions. Key data updates in 2026 will inform future development, with redosing flexibility and regulatory engagement planned.Based on…